Nan Hu

Nan Hu

Genentech, Inc - South San Francisco / United States
Medical and Health Sciences / Biostatistics
AD Scientific Index ID: 5186000
-
person_outline Nan Hu's MOST POPULAR ARTICLES
1-) Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trialsS Ostrowitzki, T Bittner, KM Sink, H Mackey, C Rabe, LS Honig, ...JAMA neurology 79 (11), 1113-1121, 2022962022
2-) Wait-list outcomes for adults with congenital heart disease listed for heart transplantation in the USLI Alshawabkeh, N Hu, KD Carter, AR Opotowsky, KA Light-McGroary, ...Journal of the American College of Cardiology 68 (9), 908-917, 2016942016
3-) Baseline demographic, clinical, and cognitive characteristics of the Alzheimer\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'s Prevention Initiative (API) Autosomal‐Dominant Alzheimer\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'s Disease Colombia TrialS Rios‐Romenets, F Lopera, KM Sink, N Hu, Q Lian, H Guthrie, J Smith, ...Alzheimer\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'s & Dementia 16 (7), 1023-1030, 2020152020
4-) Sex differences in cognitive resilience in preclinical autosomal‐dominant Alzheimer\'s disease carriers and non‐carriers: baseline findings from the API ADAD Colombia TrialC Vila‐Castelar, PN Tariot, KM Sink, D Clayton, JB Langbaum, ...Alzheimer\'s & Dementia 18 (11), 2272-2282, 2022162022
5-) Safety, tolerability, and pharmacokinetics of high‐volume subcutaneous crenezumab, with and without recombinant human hyaluronidase in healthy volunteersMJ Dolton, A Chesterman, A Moein, KM Sink, A Waitz, K Blondeau, ...Clinical Pharmacology & Therapeutics 110 (5), 1337-1348, 2021142021